Home › Astrocytoma
Astrocytoma clinical trials recruiting in the U.S.
45 studies for Astrocytoma are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX14 studies
- Boston, MA13 studies
- New York City, NY9 studies
- Chicago, IL9 studies
- Miami, FL7 studies
- Philadelphia, PA7 studies
- Seattle, WA7 studies
- Columbus, OH6 studies
- Durham, NC6 studies
- Washington, DC6 studies
- San Francisco, CA5 studies
- Cincinnati, OH5 studies
- Aurora, CO5 studies
- Salt Lake City, UT4 studies
- Baldwin Park, CA4 studies
- Lexington, KY3 studies
- New Haven, CT3 studies
- Queens, NY3 studies
- Kansas City, KS3 studies
- Nashville, TN3 studies
- Pittsburgh, PA3 studies
- Birmingham, AL3 studies
- Detroit, MI3 studies
- Ann Arbor, MI3 studies
- Edison, NJ3 studies
- San Antonio, TX3 studies
- Dallas, TX3 studies
- Rochester, MN3 studies
- St. Louis, MO3 studies
- Los Angeles, CA3 studies
By state
- Alabama3 studies
- California10 studies
- Colorado5 studies
- Connecticut3 studies
- District of Columbia4 studies
- Florida9 studies
- Illinois9 studies
- Kansas3 studies
- Kentucky4 studies
- Massachusetts13 studies
- Michigan6 studies
- Minnesota5 studies
- Missouri4 studies
- New Jersey3 studies
- New York9 studies
- North Carolina7 studies
- Ohio8 studies
- Pennsylvania8 studies
- Tennessee4 studies
- Texas15 studies
- Utah4 studies
- Virginia3 studies
- Washington8 studies
- Wisconsin3 studies
Recently updated studies
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT03896568Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT05765812VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma
RecruitingPhase 2
Ages 18 to 98 · All sexes · Updated Sep 21, 2026 · NCT07831369A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Sep 14, 2026 · NCT05698524SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
RecruitingPhase 1/2
Ages 2 to 24 · All sexes · Updated Sep 11, 2026 · NCT04923126FearLess in NeuroOncology
Recruiting
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06989086Targeted Pediatric High-Grade Glioma Therapy
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06860594Serial MRI Scans During Radiation Therapy
Recruiting
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT04188535Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 2, 2026 · NCT07215910Study of Olutasidenib and Temozolomide in HGG
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Aug 14, 2026 · NCT06344130Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT07544992Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Aug 12, 2026 · NCT05417594Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT07733674Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT04623931Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT06815029Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 24, 2026 · NCT07468136A Study of 177Lu-PSMA-617 in People With Gliomas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT07223034Loupe-Based Intraoperative Fluorescence Imaging
RecruitingObservational study
Ages 18 to 90 · All sexes · Updated Jun 3, 2026 · NCT04780009Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 1, 2026 · NCT01269853From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.